UK Markets open in 3 hrs 45 mins

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
14.42+0.12 (+0.84%)
At close: 04:00PM EST
14.47 +0.05 (+0.35%)
After hours: 05:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.30
Bid14.35 x 4000
Ask14.48 x 4000
Day's range14.29 - 14.56
52-week range13.17 - 19.97
Avg. volume2,872,791
Market cap44.921B
Beta (5Y monthly)1.08
PE ratio (TTM)11.08
EPS (TTM)1.30
Earnings dateN/A
Forward dividend & yield0.80 (5.83%)
Ex-dividend date29 Sept 2021
1y target est17.76
  • Motley Fool

    3 Healthcare Stocks With High Dividends

    So far 2022 has been brutal for growth stocks. A good place to hide might be the healthcare sector. It's a great defensive play, as healthcare is as basic as food. And these stocks all pay a nice dividend.

  • Business Wire

    Takeda Named Global Top Employer for Fifth Consecutive Year

    OSAKA, Japan & CAMBRIDGE, Mass., January 20, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast co

  • Business Wire

    Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

    OSAKA, Japan & CAMBRIDGE, Mass., January 10, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takeda’s President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global